BEMPEGALDESLEUKIN for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 45 adverse event reports in the FDA FAERS database where BEMPEGALDESLEUKIN was used for Renal cell carcinoma.
Most Reported Side Effects for BEMPEGALDESLEUKIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Acute kidney injury | 9 | 5.2% | 1 | 8 |
| Cerebrovascular accident | 9 | 5.2% | 1 | 9 |
| Hypotension | 9 | 5.2% | 0 | 9 |
| Atrial fibrillation | 7 | 4.0% | 0 | 6 |
| Pyrexia | 7 | 4.0% | 1 | 7 |
| Malignant neoplasm progression | 6 | 3.5% | 4 | 5 |
| Eosinophilia | 5 | 2.9% | 0 | 5 |
| Pulmonary embolism | 5 | 2.9% | 2 | 5 |
Other Indications for BEMPEGALDESLEUKIN
Malignant melanoma (30)
Transitional cell carcinoma (26)
Non-small cell lung cancer (13)
Metastatic renal cell carcinoma (6)
Sarcoma (6)
Metastatic malignant melanoma (5)
Triple negative breast cancer (5)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)